Terms of use

Privacy

Privacy Settings

Imprint

Contact Us

Carolina Teichmann Cravo

Get in touch and send us an email.

Want to know more?

Linkedin

Facebook

About Us

Why Redcare?

Facts & Figures

Public Affairs

Our Company

About Redcare

News & Events

Sign up

Newsroom

Our Impact

Offset

Sustainability

Overview

Share

News

Events and Publications

Corporate Governance

Contact

Investor Relations

Our Culture

Teams

Jobs

FAQs

Career

No results found

About us

Careers

LinkedIn

Twitter

Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.

Sevenum, the Netherlands, 10 January 2024. Redcare Pharmacy’s release of preliminary and unaudited sales data for Q4 and full year 2023 shows that the Group achieved the highest sales ever in a single quarter as well as record sales for the whole year, reaching the top end of its guidance for 2023 of EUR 1.7-1.8bn total sales. In Q4, Group sales amounted to EUR 531 million, an increase of 62.1% from the previous year’s EUR 328 million. Excluding MediService, sales were EUR 402 million. For the entire year, Group sales increased from EUR 1.2 billion sales last year to EUR 1.8 billion this year. Non-Rx grew 23.3% in Q4, and 24.9% or by EUR 267M to EUR 1.3 billion for total 2023.   

Redcare Pharmacy’s CEO, Olaf Heinrich comments: “During 2023 we as Redcare Pharmacy set many new records and proved our ability to generate strong growth and improve our profitability at the same time. We continued to achieve high customer satisfaction, seamlessly handling increased volumes and a growing active customer base, and expanded our leadership throughout Europe. We thank our colleagues for their dedication and for achieving these great results.”

In Q4, sales in the DACH segment (Germany, Austria and Switzerland) increased by 69% to EUR 440 million (Q4 2022: EUR 261 million). Excluding MediService, sales in DACH grew by 19% to EUR 311 million. Non-Rx sales in DACH increased 19% to EUR 271 million (Q4 2022: EUR 227 million), while prescription medication sales (Rx) rose by 397% to EUR 169 million. Excluding the sales of MediService, Rx sales were EUR 40 million in Q4, a growth of 17% versus the prior year. In full year 2023, sales in the DACH segment grew 55% and reached EUR 1.5 billion (FY 2022: EUR 940 million).

In the International segment (Belgium, Italy, France, and the Netherlands) sales increased 36% to EUR 91 million in Q4 (Q4 2022: EUR 67 million). In full year 2023, growth in International stood at 31%, with sales at EUR 345 million (FY 2022: EUR 264 million).

All published figures are preliminary and unaudited. Redcare Pharmacy N.V. will release the full annual report for the fiscal year 2023 on 5 March 2024.

Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers over 10 million active customers a wide range of more than 150,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands.

Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.

Redcare Pharmacy’s release of preliminary and unaudited sales data for Q4 and full year 2023 shows that the Group achieved the highest sales ever in a single quarter as well as record sales for the whole year, reaching the top end of its guidance for 2023 of EUR 1.7-1.8bn total sales.